Theros

Status: Active Trial | Marker: EGFR Title Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabolic response to osimertinib...

CEGF816X2102

Status: Active Trial | Marker: EGFR Title A phase Ib, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFRmutant NSCLC Study Number NCT0333343 Indication This is...

EATON

Status: Active Trial | Marker: EGFR Title An open-label, multicenter, phase I dose-escalation trial of EGF816 and trametinib in patients with non-small cell lung cancer and acquired EGFR p.T790M positive resistance to 1st or 2nd generation EGFR TKI therapy Study...